Exhaled Carbon Monoxide (eCO) for Diffusing Capacity (DLCO) Correction
Validation of Exhaled Carbon Monoxide for DLCO Correction
1 other identifier
interventional
100
1 country
2
Brief Summary
The purpose of this study is to check the accuracy of a procedure called exhaled carbon monoxide (eCO) testing. Exhaled carbon monoxide is used by physicians to help assess breathing in people with conditions like asthma and emphysema. eCO may be used to correct another breathing test (called diffusing capacity, or DLCO). Blood collection is usually required to correct the DLCO, so validation of the eCO test may help avoid that blood collection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2010
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2010
CompletedFirst Submitted
Initial submission to the registry
May 14, 2010
CompletedFirst Posted
Study publicly available on registry
May 19, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2011
CompletedNovember 9, 2011
November 1, 2011
1.5 years
May 14, 2010
November 7, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Exhaled carbon monoxide as a predictor of carboxyhemoglobin
Exhaled carbon monoxide will be evaluated as a predictor of carboxyhemoglobin and change in diffusing capacity with increasing carboxyhemoglobin
1 year
Study Arms (1)
PFT's, eCO, and pulse oximetry
OTHERAll subjects in the study will undergo complete pulmonary function testing (spirometry, blood collection for carboxyhemoglobin, diffusing capacity); exhaled carbon-monoxide testing, and pulse oximetry.
Interventions
exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO
Eligibility Criteria
You may qualify if:
- Patients who will at minimum have spirometry, diffusing capacity and CO-oximetry performed for any clinical indication (Part 1 only)
- Willingness to under go the study procedures.
- Ability to give written informed consent to participate in the study.
You may not qualify if:
- Subjects on oxygen therapy within 1 hour. High levels of oxygen are used to displace CO in cases of toxicity. Presumably those recently on lower flows of oxygen are not in a steady state for several half-lives.
- Self-reported smoking within 1-hour.
- Significant exercise within 15 minutes
- Recent (within 2 hrs) alcohol consumption (alcohol can interfere with the DLCO measurement)
- Subjects unwilling to remove nail polish from one finger
- Known atypical hemoglobin types (e.g. sickle cell trait or disease, thalassemia etc). The binding and release of oxygen and presumably CO is altered in these types of hemoglobinopathies
- History of known or suspected alveolar hemorrhage. Free hemoglobin or red cells in the alveolus markedly raise the DLCO and theoretically might alter the eCO.
- Known or suspected intestinal bacterial overgrowth. Although the cross reactivity of the CO sensor for hydrogen is \<2%, high values of hydrogen from bacterial overgrowth, may lead to erroneous CO measurements.
- Tracheostomy or inability to form a tight seal around the mouthpiece.
- Prior participation in the same part of this study (i.e., subjects can participate in Part 1 and Part 2, but not twice in Part 1, or twice in Part 2)
- Inability to perform spirometry and diffusing capacity
- Inability to consent
- Other diseases or conditions that may, in the opinion of the investigator, result in invalid pulmonary function tests or eCO measurement.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
UCLA
Los Angeles, California, 90095, United States
West LA VA
Los Angeles, California, 90095, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michelle R Zeidler, MD
UCLA, VA
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
May 14, 2010
First Posted
May 19, 2010
Study Start
May 1, 2010
Primary Completion
November 1, 2011
Study Completion
November 1, 2011
Last Updated
November 9, 2011
Record last verified: 2011-11